Morepen Laboratories has launched its first prescription (Rx) generic product, Desloratadine Tablets USP, 5 mg, in 100-count and 500-count packs, for distribution in the U.S. market. The initiative is being undertaken through its wholly owned U.S. arm, Morepen Bio Inc. The company has been supplying Desloratadine API to the U.S. market for many years. Building on this established API position, the latest launch extends the company's participation further along the pharmaceutical value chain into finished-dosage medicines and U.S. distribution.
The prescription generics expansion follows Morepen Laboratories' earlier U.S. OTC product introductions. Separately, the company has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Phosphate Tablets USP, 25 mg, 50 mg and 100 mg. This lunch demonstrates the company's growing capabilities in formulation development, analytical science and regulatory filings. The application is currently under regulatory review.
Morepen Laboratories is engaged in the manufacturing and sale of APis/ Bulk Drugs, Home Diagnostics, Formulations and OTC products.